Condition: Solid Tumor, Solid Carcinoma, Uroepithelial Carcinoma, Bladder Cancer, Prostate Cancer, Lung Cancer, Nasopharyngeal Cancer, Liver Cancer, Cholangiocarcinoma, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Thyroid Cancer, Head and Neck Cancer

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT06851663

Sponsor: RenJi Hospital

Phase: Phase 2/Phase 3

Eligibility:

• Age: minimum 18 Years maximum 75 Years
• Gender: All

Inclusion Criteria:

• Aged 18-75 year-old and of either sex
• Histologically confirmed diagnosis of solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) or suspected solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) by diagnostic imaging;
• Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.

Exclusion Criteria:

• Pregnancy；
• Severe hepatic and renal insufficiency;
• Allergic to single-domain antibody radiopharmaceuticals.

View trial on ClinicalTrials.gov